EUCTR2012-003025-25-Outside-EU/EEA进行中（未招募）不适用
A phase III, double-blind, randomized, controlled study to evaluate the immunogenicity and safety of GlaxoSmithKline (GSK) Biologicals’ HPV-16/18 L1 VLP AS04 vaccine administered intramuscularly according to a 0, 1, 6-month schedule in healthy Chinese female subjects aged 9-17 years. - HPV-058
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 入组人数
- 750
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- Female
入选标准
- •Subjects who the investigator believes that they or their parent(s)/Legally Acceptable Representative(s) (LAR) can and will comply with the requirements of the protocol (e.g. completion of the diary cards, return for follow-up visits).
- •Healthy Chinese females between and including 9 and 17 years of age at the time of the first vaccination.
- •Written informed consent obtained from the parent(s)/LAR(s) of the subject and informed assent obtained from the subject, if appropriate, prior to enrolment.
- •Healthy subjects as established by medical history and history-directed clinical examination before entering into the study.
- •Subjects must not be pregnant. Absence of pregnancy will be verified with a urine pregnancy test before each vaccination.
- •Subjects must be either of non-childbearing potential (e.g. pre-menarcheal or surgically sterilised), or if of childbearing potential, they must be abstinent or have practiced adequate contraception for 30 days prior to vaccination, have a negative pregnancy test and agree to continue such precautions for 2 months after completion of the vaccination series.
- •Are the trial subjects under 18? yes
- •Number of subjects for this age range: 750
- •F.1.2 Adults (18-64 years) no
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •Use of any investigational or non-registered product (drug or vaccine) other than the study vaccines within 30 days preceding the first dose of study vaccine, or planned use during the study period.
- •Chronic administration (defined as more than 14 days) of immunosuppressants or other immune-modifying drugs within six months prior to the first vaccine dose. (For corticosteroids, this will mean prednisone > 0.5 mg/kg/day or equivalent. Inhaled and topical steroids are allowed.)
- •Planned administration/administration of a vaccine not foreseen by the study protocol within 30 days before and 30 days after (i.e., Days 0-29) the first dose of vaccine.
- •Concurrently participating in another clinical study, at any time during the study period (i.e. from Day 0 up to the telephone contact at Month 12), in which the subject has been or will be exposed to an investigational or a non-investigational product (pharmaceutical product or device).
- •A subject planning to become pregnant, likely to become pregnant (as determined by the investigator) or planning to discontinue contraceptive precautions during the study period and up to two months after the last vaccine dose.
- •Pregnant or breastfeeding. Subjects must be at least three months post-pregnancy and not breastfeeding to enter the study.
- •Previous vaccination against HPV or planned administration of any HPV vaccine other than that foreseen by the protocol during the study period.
- •Previous administration of components of the study vaccine (MPL or AS04 adjuvant).
- •History of chronic condition(s) requiring treatment such as cancer or autoimmune disease.
- •History of allergic disease, suspected allergy or reactions likely to be exacerbated by any component of the vaccine (e.g. aluminium).
- •Hypersensitivity to latex (found in syringe-tip cap and plunger).
- •Any confirmed or suspected immunosuppressive or immunodeficient condition, based on medical history and physical examination (no laboratory testing required).
- •Acute disease at the time of enrolment. (Acute disease is defined as the presence of a moderate or severe illness with or without fever. All vaccines can be administered to persons with a minor illness such as diarrhoea, mild upper respiratory infection with or without low-grade febrile illness, i.e., oral/axillary temperature >37.0°C).
- •Administration of immunoglobulins and/or any blood products within the three months preceding the first dose of study vaccine or planned administration during the study period.
研究者
相似试验
进行中（未招募）
不适用
A phase III, double-blind, randomized, controlled study to evaluate the safety and immunogenicity of GlaxoSmithKline Biologicals’ HPV-16/18 VLP/AS04 vaccine administered intramuscularly according to a 0, 1, 6 month schedule in healthy female subjects aged 10 – 14 years.Sponsor’s protocol code number, version, and date: , Final version, 17th March 2004Name or abbreviated title of the trial where available: HPV-013 - HPV-013cervical cancer: the study is conducted in healthy female adolescentsEUCTR2004-000518-37-NOGlaxoSmithKline AS2,000
进行中（未招募）
不适用
A study to evaluate safety, immunogenicity and efficacy of GSK Biologicals HPV-16/18 L1/AS04 vaccine administered intramuscularly according to a three-dose schedule (0, 1, 6 month) in healthy adult female subjects aged 26 years and above.For active immunization of girls and women from 10 years of age onwards for the prevention of persistent human papillomavirus (HPV) infections and related clinical outcomes (cytological abnormalities and pre-cancerous lesions) caused by oncogenic HPV types 16 and 18.MedDRA version: 14.1Level: LLTClassification code 10063001Term: Human papilloma virus infectionSystem Organ Class: 100000004862EUCTR2005-002546-20-PTGlaxoSmithKline Biologicals5,751
已完成
3 期
A phase III, double-blind, randomized, controlled study to evaluate the safety, immunogenicity and efficacy of GlaxoSmithKline Biologicals* HPV 16/18 L1/AS04 vaccine administered intramuscularly according to a three-dose schedule (0, 1, 6 month) in healthy adult female subjects aged 26 years and above.Human Papillomavirus vaccination100474381003859410013364Cervical cancerNL-OMON38271GlaxoSmithKline360
进行中（未招募）
1 期
Human Papilloma Virus (HPV) Vaccine Trial in Young Adolescent Women With GSK Biologicals' (GSK Bio) HPV-16/18 Vaccinecervical cancer: the study is conducted in healthy female adolescentsMedDRA version: 14.1Level: LLTClassification code 10063001Term: Human papilloma virus infectionSystem Organ Class: 10021881 - Infections and infestationsEUCTR2004-000518-37-ESGlaxoSmithKline SA
进行中（未招募）
1 期
A phase III, double-blind, randomized, controlled study to evaluate the safety, immunogenicity and efficacy of GlaxoSmithKline Biologicals’ HPV 16/18 L1/AS04 vaccine administered intramuscularly according to a three-dose schedule (0, 1, 6 month) in healthy adult female subjects aged 26 years and above. - HPV-015EUCTR2005-002546-20-GBGlaxoSmithKline Biologicals5,782